Clinical evaluation of henagliflozin combined with Huangkui capsules in treatment of patients with diabetic kidney disease
LI Shen
LI Dongfeng
LI Ying
YAN Chengjun
Abstract：Objective To explore the therapeutic effect of henagliflozin combined with Huangkui capsules on di-abetic kidney disease(DKD).Methods A total of 108 inpatients with DKD admitted to the Affiliated Hospital of Western Anhui Health Vocational College from August 2023 to August 2024 were enrolled in the study and divided into the control group(n=54,oral administration of Huangkui capsules on top of standard therapy)and the observation group(n=54,re-ceived henagliflozin in addition to the control group regimen)by the lottery method.The clinical efficacy,blood glucose control(2-hour postprandial glucose(2hPG),glycated hemoglobin(HbA1c),fasting plasma glucose(FPG)),renal func-tion indicators(urinary albumin excretion rate(UAER),serum creatinine(Scr)),inflammatory factors(C-reactive pro-tein(CRP),interleukin-6(IL-6))and adverse reactions were compared between the two groups before and after treatment.Results After treatment,the total effective rates of the observation group and the control group were 90.75%(49/54)and 75.93%(41/54),respectively(χ2=4.267,P<0.05).The differences in glycated hemoglobin((6.35±0.84)%vs(7.45±0.83)%),2hPG((8.26±0.74)mmol/L vs(9.65±0.73)mmol/L)and fasting blood glucose((5.51±0.75)mmol/L vs(6.05±0.73)mmol/L)between the observation group and the control group were all statistically significant(t=6.845,9.120,3.791,all P<0.05).Similarly,the differences in UAER((98.65±11.35)mg/24 h vs(114.35±11.32)mg/24 h)and Scr((94.53±13.52)μmol/L vs(105.35±12.32)μmol/L)between the two groups were statistically significant(t=7.197,4.347,both P<0.05).Furthermore,the differences in CRP((2.54±0.51)mg/L vs(3.45±0.53)mg/L)and IL-6((8.56±1.54)pg/mL vs(11.35±1.52)pg/mL)be-tween the two groups were also statistically significant(t=9.092,9.475,both P<0.05).The incidence rates of adverse reactions showed no statistically significant difference between the observation group and the control group(7.41%(4/54)vs 3.70%(2/54))(χ2=0.706,P>0.05).Conclusion Huangkui capsules combined with henagliflozin for DKD patients can enhance the clinical efficacy,reduce the blood glucose,and improve the renal function and inflammatory response,with good safety.
Keywords：henagliflozinHuangkui capsulesdiabetic kidney diseaseclinical efficacyrenal functionblood glucose
Publication Date：2025-10-25
Online Publishing Date：2025-11-03(First online date of this platform, not the publication date of the document)
Pages：4( 1197-1200 )